Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43801   clinical trials with a EudraCT protocol, of which   7259   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-002101-21
    Sponsor's Protocol Code Number:ARGX-113-1803
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2020-02-20
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2019-002101-21
    A.3Full title of the trial
    A Phase 3, Multicenter, Open-label, Long-term Trial to Evaluate the Safety and Efficacy of Efgartigimod (ARGX-113) 10 mg/kg Intravenous in Adult Patients with Primary Immune Thrombocytopenia
    Étude de phase III, multicentrique, en ouvert, à long terme visant à évaluer la sécurité et l’efficacité de l’efgartigimod (ARGX-113) à 10 mg/kg par voie intraveineuse chez des patients adultes atteints de purpura thrombopénique immunologique primaire
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A long-term study to assess the safety and efficacy of efgartigimod in adult patients with primary immune thrombocytopenia (an autoimmune disorder that destructs platelets, blood cells that help with clotting, and can lead to easy or excessive bruising and bleeding)
    Étude de phase III, à long terme visant à évaluer la sécurité et l’efficacité de l’efgartigimod chez les patients adultes atteints de thrombocytopénie immune primaire (maladie auto-immune qui détruit les plaquettes, cellules sanguines qui contribuent à la coagulation, et susceptible d'entraîner l'apparition rapide ou excessive d'ecchymoses et de saignements)
    A.3.2Name or abbreviated title of the trial where available
    ADVANCE+
    A.4.1Sponsor's protocol code numberARGX-113-1803
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of Sponsorargenx BVBA
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportargenx BVBA
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationargenx BVBA
    B.5.2Functional name of contact pointRegulatory
    B.5.3 Address:
    B.5.3.1Street AddressIndustriepark Zwijnaarde 7
    B.5.3.2Town/ cityZwijnaarde
    B.5.3.3Post codeB-9052
    B.5.3.4CountryBelgium
    B.5.4Telephone number+32 9 310 3400
    B.5.5Fax number+32 9 310 3499
    B.5.6E-mailregulatory@argenx.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameEfgartigimod
    D.3.2Product code ARGX-113
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNEfgartigimod alfa
    D.3.9.1CAS number 1821402-21-4
    D.3.9.2Current sponsor codeARGX-113
    D.3.9.3Other descriptive nameARGX-113
    D.3.9.4EV Substance CodeSUB180001
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Primary immune thrombocytopenia
    Purpura thrombopénique immunologique primaire
    E.1.1.1Medical condition in easily understood language
    Disorder that can lead to easy or excessive bruising and bleeding due low levels of the cells that help blood clot
    Maladie susceptible d'entraîner l'apparition rapide ou excessive d'ecchymoses et de saignements en raison du faible taux de cellules qui contribuent à la coagulation sanguine
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10050245
    E.1.2Term Autoimmune thrombocytopenia
    E.1.2System Organ Class 100000004851
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the long-term safety of efgartigimod in adult patients with primary immune thrombocytopenia (ITP).
    Évaluer la sécurité à long terme de l’efgartigimod chez des patients adultes atteints de purpura thrombopénique immunologique primaire (PTI).
    E.2.2Secondary objectives of the trial
    • To evaluate the long-term efficacy of efgartigimod on overall platelet count response.
    • To explore the potential for reduction in concurrent ITP therapy.
    • To evaluate the effects of efgartigimod treatment on quality-of-life (QoL) measures and patient-reported outcomes (PRO).
    • To assess the pharmacodynamic (PD) effects of efgartigimod.
    • To evaluate the pharmacokinetics (PK) of efgartigimod.
    • To assess the immunogenicity of efgartigimod.
    •Évaluer l’efficacité à long terme de l’efgartigimod sur la réponse globale du taux de plaquettes.
    •Explorer les diminutions potentielles des traitements concomitants du PTI.
    •Évaluer les effets du traitement par efgartigimod sur les mesures de la qualité de vie (QdV) et sur les résultats rapportés par le/la patient(e).
    •Mesurer les effets pharmacodynamiques (PD) de l’efgartigimod.
    •Évaluer la pharmacocinétique (PK) de l’efgartigimod.
    •Évaluer l’immunogénicité de l’efgartigimod.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Ability to understand the requirements of the trial, to provide written informed consent (including consent for the use and disclosure of research-related health information), and to comply with the trial protocol procedures (including required trial visits).
    2. Patients enrolled in the ARGX-113-1801 trial who completed the 24-week treatment period.
    3. Women of childbearing potential must have a negative urine pregnancy test at baseline before trial medication (infusion) can be administered. Women are considered of childbearing potential unless they are post-menopausal (defined by continuous amenorrhea) for at least 1 year with a FSH of >40 IU/L or are surgically sterilized (i.e. women who had a hysterectomy, both ovaries surgically removed, or have a documented permanent female sterilization procedure including tubal ligation). Follicle-stimulating hormone can be used to confirm post-menopausal status in amenorrheic patients not on hormonal replacement therapy.
    4. Women of childbearing potential should use a highly effective method of contraception (i.e. pregnancy rate of less than 1% per year) during the trial and for 90 days after the last administration of the IMP. They must be on a stable regimen, for at least 1 month:
    • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation
    - oral
    - intravaginal
    - transdermal
    • progestogen-only hormonal contraception associated with inhibition of ovulation:
    - oral
    - injectable
    - implantable
    • intrauterine device (IUD)
    • intrauterine hormone-releasing system
    • bilateral tubal occlusion
    • vasectomized partner(provided that the partner is the sole sexual partner of the trial participant and that aspermia was documented post procedure)
    • continuous abstinence from heterosexual sexual contact. Sexual abstinence is only allowable if it is the preferred and usual lifestyle of the patient. Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not acceptable.
    5. Non-sterilized male patients who are sexually active with a female partner of childbearing potential must use effective double contraception, being a condom for male patients and a highly effective form of contraception for the female partner of childbearing potential (same as for female patients described in inclusion criterion 4). Male patients practicing true sexual abstinence (when this is in line with the preferred and usual lifestyle of the participant) can be included. Sterilized male patients who have had vasectomy with documented aspermia post procedure can be included. In addition, male patients are not allowed to donate sperm during this period from signing of informed consent form, throughout the duration of the trial, and for 90 days after the last administration of IMP.
    1.Capacité à comprendre les exigences de l’étude, à fournir un consentement éclairé écrit (y compris un consentement à l’utilisation et au partage des informations médicales liées à l’étude) et à se conformer aux procédures du protocole de l’étude (notamment les visites d’étude).
    2.Les patients inclus dans l’étude ARGX-113-1801 et qui ont terminé les 24 semaines de la période de traitment de l’étude.
    3.Les femmes aptes à procréer doivent présenter un test de grossesse urinaire négatif à l’inclusion avant toute administration (perfusion) du médicament de l’étude. Les femmes sont considérées aptes à procréer sauf si elles sont ménopausées (c’est-à-dire en aménorrhée continue) depuis au moins un an avec un taux d’hormones folliculostimulantes (FSH) supérieur à 40 UI/l, ou si elles ont eu recours à une stérilisation chirurgicale (par exemple, hystérectomie, double ovariectomie ou procédure de stérilisation permanente documentée comme la ligature des trompes). L’hormone folliculostimulante peut servir à confirmer la ménopause chez des patientes en aménorrhée qui ne suivent pas de traitement hormonal de substitution.
    4.Les femmes aptes à procréer doivent utiliser une méthode de contraception hautement efficace (c’est-à-dire avec un taux de grossesse inférieur à 1 % par an) pendant l’étude et pendant 90 jours après la dernière administration du ME. Elles doivent être sous un traitement stable pendant au moins un mois de :
    •contraception hormonale combinée (contenant ┼ôstrogènes et progestatifs) associée à une inhibition de l’ovulation :
    -par voie orale,
    -intravaginale,
    -transdermique ;
    •contraception hormonale par progestatifs seuls associée à une inhibition de l’ovulation :
    -par voie orale,
    -injectable,
    -implantable ;
    •dispositif intra-utérin (DIU) ;
    •système intra-utérin à libération d’hormone ;
    •ligature bilatérale des trompes ;
    •vasectomie du partenaire (à condition que le partenaire soit le seul partenaire sexuel de la participante à l’étude et que l’aspermie ait été documentée après la procédure) ;
    •abstinence continue de tout rapport hétérosexuel. L’abstinence n’est acceptable que si elle correspond au mode de vie de la patiente. L’abstinence périodique (calendrier, méthode sympto-thermique, méthodes post-ovulation) n’est pas acceptable.
    5.Les patients masculins qui sont sexuellement actifs avec une partenaire féminine apte à procréer doivent utiliser deux moyens de contraception hautement efficaces, par exemple, un préservatif masculin et une méthode de contraception hautement efficace pour la partenaire féminine apte à procréer (voir les méthodes de contraception décrites au critère d’inclusion no 4). Les patients masculins pratiquant l’abstinence totale (si cela correspond au mode de vie de prédilection du patient) peuvent être inclus. Les patients masculins stérilisés qui ont eu recours à une vasectomie avec aspermie documentée après la procédure peuvent être inclus. De plus, les patients masculins ne sont pas autorisés à donner leur sperme à partir de la signature du formulaire de consentement éclairé, tout au long de l’étude et jusqu’à 90 jours après la dernière administration du ME.
    E.4Principal exclusion criteria
    1. Introduction or continuation of non-permitted medications during the ARGX-113-1801 trial (such as anti-CD20 therapy, romiplostim, fostamatinib, monoclonal antibodies, or Fc fusion proteins).
    2. Pregnant or lactating women, and those intending to become pregnant during the trial or within 90 days after the last dosing.
    3. Patients with known medical history of hypersensitivity to any of the ingredients of efgartigimod.
    4. Use of any other investigational drug or participation in any other investigational trial.
    1.Introduction ou poursuite de traitements non autorisés pendant l’étude ARGX-113-1801 (tels que traitement anti-CD20, romiplostime, fostamatinib, anticorps monoclonaux ou protéines de fusion Fc).
    2.Femmes enceintes ou qui allaitent, ou qui souhaitent tomber enceintes pendant l’étude ou dans les 90 jours suivant la dernière administration.
    3.Patients avec antécédents d’hypersensibilité à l’un des ingrédients de l’efgartigimod.
    4.Utilisation d’un autre médicament expérimental ou participation à une autre étude clinique.
    E.5 End points
    E.5.1Primary end point(s)
    Frequency and severity of AEs, vital signs, and laboratory assessments.
    Fréquence et gravité des EI, constantes vitales et analyses biologiques.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Frequency and severity of AEs - at each visit
    Vital signs - at baseline visit (week 1), followed by every even week (week 2 to week 52) and Early discontinuation, follow-up 1 and 2, unscheduled visits.
    Laboratory assessments - please refer to protocol Table 1 Schedule of Assessments for various laboratory assessments
    Fréquence et gravité des EI - à chaque visite
    Signes vitaux - lors de la visite de référence (semaine 1), suivie de chaque semaine paire (semaine 2 à semaine 52) et Arrêt précoce, suivi 1 et 2, visites non prévues.
    Évaluations en laboratoire - veuillez vous reporter au tableau 1 du protocole des évaluations pour les diverses évaluations en laboratoire
    E.5.2Secondary end point(s)
    1. Extent of disease control defined as the number of cumulative weeks over the planned 52-week treatment period with platelet counts of ≥50×10^9/L.
    2. Percentage of patients with overall platelet count response defined as achieving a platelet count of ≥50×10^9/L on at least 4 occasions at any time during the 52-week treatment period.
    3. Mean change from baseline in platelet count at each visit.
    4. For patients rolling-over from the ARGX-113-1801 trial with a platelet count of <30×10^9/L: time to response is defined as the time to achieve 2 consecutive platelet counts of ≥50×10^9/L.
    5. The number of cumulative weeks over the planned 52-week treatment period with platelet counts of ≥30×10^9/L and at least 20×10^9/L above baseline.
    6. In patients with baseline platelet count of <15×10^9/L in the current trial (ARGX-113-1803), the number of cumulative weeks over the planned 52-week treatment period with platelet counts of ≥30×10^9/L and at least 20×10^9/L above baseline.
    7. In patients with first exposure to efgartigimod: proportion of patients who achieve a sustained platelet response defined as achieving platelet counts of at least 50×10^9/L for at least 4 of the 6 visits between visit 19 and 24 of the trial.
    8. In patients with first exposure to efgartigimod: proportion of patients in the overall population achieving platelet counts of at least 50×10^9/L for at least 6 of the 8 visits between visits 17 and 24 of the trial.
    9. Rate of receipt of rescue therapy (rescue per patient per month).
    10. Reduction in concurrent ITP therapy.
    11. Incidence and severity of the WHO-classified bleeding events.
    12. Change from baseline in PRO (FACIT-Fatigue, Fact-Th6) and QoL (SF-36) at planned visits.
    13. Incidence of anti-drug antibodies (ADA) to efgartigimod.
    14. Pharmacodynamics markers: total IgG, IgG isotypes (IgG1, IgG2, IgG3, IgG4).
    1.Contrôle de l’étendue de la maladie, défini comme le nombre de semaines cumulées sur les 52 semaines prévues de la période de traitement où le taux de plaquettes est supérieur ou égal à 50 × 109/l.
    2.Pourcentage de patients avec réponse globale concernant le taux de plaquettes défini comme un taux de plaquettes supérieur ou égal à 50 × 109/l à au moins quatre occasions à tout moment pendant les 52 semaines de la période de traitement.
    3.Variation moyenne du taux de plaquettes par rapport à l’inclusion à chaque visite.
    4.Pour les patients participant à nouveau après l’étude ARGX-113-1801 avec un taux de plaquettes inférieur à 30 x 109/l : le temps de réponse se définit comme le temps nécessaire pour obtenir deux fois de suite un taux de plaquettes supérieur ou égal à 50 x 109/l.
    5.Nombre de semaines cumulées sur les 52 semaines prévues de la période de traitement où le taux de plaquettes est supérieur ou égal à 30×109/l et au moins à 20 x 109/l au-dessus du taux de plaquettes à l’inclusion.
    6.Pour les patients avec un taux de plaquettes à l’inclusion inférieur à 15 x 109/l dans l’étude en cours (ARGX-113-1803), le nombre de semaines cumulées sur les 52 semaines prévues de la période de traitement où le taux de plaquettes est supérieur ou égal à 30×109/l et au moins à 20 x 109/l au-dessus du taux de plaquettes à l’inclusion.
    7.Pour les patients exposés pour la première fois à l’efgartigimod : la proportion de patients dont la réponse du taux de plaquettes est maintenue, à savoir au moins 50 x 109/l pendant au moins quatre des six visites entre les visites 19 et 24 de l’étude.
    8.Pour les patients exposés pour la première fois à l’efgartigimod : la proportion de patients parmi la population totale de l’étude qui obtiennent un taux de plaquettes d’au moins 50 x 109/l pendant au moins six des huit visites entre les visites 17 et 24 de l’étude.
    9.Fréquence de traitement de secours administré (par patient[e] et par mois).
    10.Diminution des traitements concomitants pour le PTI.
    11.Incidence et gravité des événements hémorragiques d’après la classification de l’OMS.
    12.Variations depuis l’inclusion des résultats rapportés par les patients (FACIT-Fatigue, Fact-Th6) et de la QdV (SF-36) lors de visites programmées.
    13.Incidence des anticorps antimédicament (AAM) sur l’efgartigimod.
    14.Marqueurs pharmacodynamiques : IgG totale, isotypes de l’IgG (IgG1, IgG2, IgG3, IgG4).
    E.5.2.1Timepoint(s) of evaluation of this end point
    1. Over the 52-week treatment period
    2. Over the 52-week treatment period
    3. At each visit
    4. At each visit
    5. Over the 52-week treatment period
    6. Over the 52-week treatment period
    7. Between visit 19 and 24
    8. Between visits 17 and 24
    9. At each visit
    10. At each visit
    11. At each visit
    12. PRO: Weeks 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 47, 49, 52 of Treatment period, Early Discontinuation
    QoL: Weeks 1, 9, 17, 25, 33, 41, 49, 52 of Treatment period, Early Discontinuation
    13. Weeks 1, 5, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 of Treatment period, Early Discontinuation, Follow-up 2, Unscheduled Visit
    14. Weeks 1, 5, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 of Treatment period, Early Discontinuation, Follow-up 1/2, Unscheduled Visit

    1.Sur la période de traitement de 52 semaines 2.Sur la période de traitement de 52 semaines 3.À chaque visite 4.À chaque visite 5.Sur la période de traitement de 52 semaines 6.Sur la période de traitement de 52 semaines 7.Entre la visite 19 et 24 8.Entre la visite 17 et 24 9.À chaque visite 10.À chaque visite 11.À chaque visite 12.PRO: Semaine 1, 5, 9, 13, 17, 21, 25, 29, 33, 37, 41, 45, 47, 49, 52 de la période de traitement, arrêt précoce QdV: Semaine 1, 9, 17, 25, 33, 41, 49, 52 de la période de traitement, arrêt précoce 13.Semaine 1, 5, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 de la période de traitement, arrêt précoce, suivi 2, visite non prévue 14.Semaine 1, 5, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52 de la période de traitement, arrêt précoce, suivi 1/2, visite non prévue
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Immunogenicity of efgartigimod
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned7
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA75
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Austria
    Belgium
    Bulgaria
    Canada
    Czech Republic
    France
    Germany
    Hungary
    Italy
    Japan
    Netherlands
    Poland
    Russian Federation
    Spain
    Ukraine
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 140
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 16
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state25
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 140
    F.4.2.2In the whole clinical trial 156
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    After a patient has completed the trial or has withdrawn/discontinued early, usual treatment will be administered if required, in accordance with the trial sites' standard of care and generally accepted medical practice depending on the patient's individual needs.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-04-17
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-04-22
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA